Abstract Number: 2108 • ACR Convergence 2023
Specific Symptom Clusters at Diagnosis Signal a Poorer Early RA Prognosis: Data from the Canadian Early Arthritis Cohort (CATCH)
Background/Purpose: Symptom clusters are stable groups of 2+ symptoms that are related to each other and frequently co-occur. Identifying symptom clusters in early RA may…Abstract Number: 057 • 2023 Pediatric Rheumatology Symposium
A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…Abstract Number: 1344 • ACR Convergence 2022
Patient-reported Outcomes in Lupus Low Disease Activity State: Impact of Fatigue
Background/Purpose: Patient Reported Outcomes (PROs) can be assessed by self-administered questionnaires and can lead to better decision-making by physicians. The aim of this study was…Abstract Number: 1458 • ACR Convergence 2022
Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with systemic lupus erythematosus (SLE). Objective prevalence rates are reported as 38% [range: 20% to 80%]…Abstract Number: 1847 • ACR Convergence 2022
Differences in Key Patient-reported Outcome Domains Identified by the Patient Acceptable Symptom State in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study)
Background/Purpose: Incorporating patient perspectives of their disease state is needed for disease activity assessment in adults with SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO). The…Abstract Number: 1945 • ACR Convergence 2022
Determinants of Patient’s Global Assessment of Disease Severity and Predictors of Disease Course in Juvenile Fibromyalgia
Background/Purpose: Juvenile Fibromyalgia Syndrome (JFS) is a disabling condition characterized by widespread musculoskeletal pain, fatigue and mood disturbances, which impact significantly on patients' quality of…Abstract Number: 2042 • ACR Convergence 2022
Sjögren’s Disease and Mitochondrial Function
Background/Purpose: Sjögren's disease (SjD) is a chronic inflammatory, autoimmune disorder with reduced lacrimal/salivary gland secretion resulting in keratoconjunctivitis sicca and xerostomia, respectively. Also, SjD patients…Abstract Number: 0127 • ACR Convergence 2022
The Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study) Supports Multidimensional Disease Symptomatology with High Levels of Pain and Fatigue, and Low Levels of Function
Background/Purpose: Quality of life (QOL) and disease impact are important to adults with SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO) but remain poorly described. Patient-reported…Abstract Number: 2104 • ACR Convergence 2022
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Background/Purpose: Manifestations of SLE can be divided into two subtypes. Type 1 SLE includes classic SLE manifestations that are driven by autoimmune inflammatory mechanisms. Type…Abstract Number: 0204 • ACR Convergence 2022
Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment
Background/Purpose: Polymyalgia rheumatica (PMR) is typified by pain and stiffness of the shoulder and hip girdles. Previous qualitative studies have highlighted the importance to patients…Abstract Number: 2111 • ACR Convergence 2022
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…Abstract Number: 0369 • ACR Convergence 2022
The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
Background/Purpose: Fatigue is among the most prevalent symptoms of systemic lupus erythematosus (SLE) and is associated with patient distress, work dysfunction, and worse overall health…Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…Abstract Number: 0390 • ACR Convergence 2022
Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients
Background/Purpose: Symptomatic onset long after recovery from the acute phase of COVID-19 infection has been reported by the population. Currently, it is not known how…Abstract Number: 2189 • ACR Convergence 2022
Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study
Background/Purpose: Fatigue is one of the most prevalent and disabling symptom reported by people with systemic sclerosis (SSc). No fatigue-specific programs exist for people with…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 14
- Next Page »